Retatrutide: −25% in phase 3, and a gray market that got there first

What it is and why the hype

Retatrutide is a triple agonist: it acts on the GLP-1, GIP and glucagon receptors at once¹¹. In phase 2 (338 adults with obesity), the 12 mg dose was associated with −24.2% body weight at 48 weeks vs −2.1% with placebo¹. In type 2 diabetes, after a phase 1b multiple-dose trial¹², phase 2 recorded weight reductions of up to 16.9% at 36 weeks vs 3.0% with placebo¹³. The number spread on social media long before any approval.

The phase 3 results

TRIUMPH-1 was published on September 29, 2026: 2,339 adults without diabetes, 80 weeks. Body weight changed −17.6%, −23.7% and −25.0% with 4, 9 and 12 mg, vs −3.9% with placebo; knee-osteoarthritis pain and sleep apnea also improved². Gastrointestinal effects were the most common². The trial, sponsored by Eli Lilly and Company, is registered as NCT05929066¹⁴.

TRIUMPH-2, in 1,152 adults with obesity and type 2 diabetes, associated the 12 mg dose with −18.8% body weight at 80 weeks vs −5.1% with placebo (a −13.8-point difference). Diarrhea (27–34% vs 13%) and nausea (14–28% vs 8%) were more frequent than with placebo, as were hypotension (1–6% vs <1%) and dysesthesia (abnormal skin sensations, 4–7% vs 1%)³.

The gray market got there first

While the trials were still running, retatrutide was already sold online as a "research peptide". In December 2024 the FDA sent a warning letter to Summit Research Peptides for selling semaglutide, tirzepatide, retatrutide, cagrilintide and mazdutide, concluding that evidence from its websites established the products were "drugs for human use"⁵. In August 2026 it sent another to Royal Peptides, whose labels said "for research use only" and "not for human or animal consumption"⁶.

The FDA keeps a page on unapproved GLP-1s warning against semaglutide, tirzepatide, retatrutide and other products sold "for research"⁴. And in August 2026 Eli Lilly sued six companies; according to Healio, Lilly says the sellers "falsely claim their drugs are for 'research-use only' when they are intended for human use"⁷. A 2026 medical review lists retatrutide among investigational drugs that an illicit market offers without a prescription, lacking an established human safety profile¹⁷.

What is in those vials?

We found no published analyses of retatrutide bought online. There are for semaglutide: a study that made test purchases from six illegal online pharmacies found, in the vials received, purity of 7.7% to 14.4% vs the 99% claimed, and endotoxin in every sample; the three pens ordered never arrived¹⁰. What does exist is a 2026 case report: a man with type 1 diabetes developed severe vomiting, ketonemia and acute kidney injury shortly after injecting an online-purchased product sold as retatrutide; a Shigella infection complicated attributing the cause¹⁵.

The region, and the rumor about Panama

In Colombia, INVIMA included retatrutide in its alert 184-2026 on fraudulent peptides offered on Instagram and a website⁸. An Argentine outlet reported in August 2026 that "countries such as Brazil, Paraguay, Colombia and Panama have already banned the sale of Retatrutide"⁹. Argentina did make it formal: ANMAT Disposition 6140/2026, published in the Boletín Oficial on September 24, 2026, banned the use, sale, advertising and distribution of products declaring retatrutide, except authorized clinical research¹⁶.